Aris Angelis

Aug 24, 2023 | journals.sagepub.com | Aris Angelis |Ajay Aggarwal |Richard Grieve |John Cairns

Given the ever-increasing prices of new drugs,1 the use of health technology assessment (HTA) by healthcare payers and insurers for guiding reimbursement and pricing decisions is becoming increasingly important for the allocation of limited resources. Clinical and economic data are analysed to judge the added clinical benefit and cost-effectiveness of new drugs versus existing treatments.

Feb 18, 2023 | dispatchist.com | Aris Angelis

Search Menu Search In a new analysis published in the British Medical Journal this week, experts argued that high pharmaceutical drug prices are not justified by biopharmaceutical companies’ spending on research and development (R&D).Aris Angelis, an assistant professor in health economics, revealed how between 1999 and 2018, the 15 largest biopharmaceutical companies in the world spent more money on selling, administrative, and general activities than fund allocation to R&D.For instance,...

Feb 16, 2023 | dispatchist.com | Aris Angelis

High drug prices are not justified by industry's spending on research and development (R&D), argue experts in The BMJ today.

Feb 13, 2023 | nature.com | Aris Angelis |Andrew H. Briggs

In the UK, England’s National Health Service (NHS England) recently launched the Innovative Medicines Fund (IMF) to fast-track promising new drugs, operating on similar terms to — and with the same £340 million budget as — the Cancer Drugs Fund (CDF)1. Both managed-access funds should be exceptional patient-access routes that are used in the case of immature evidence on a drug’s value from randomized interventional studies.